Cargando…

Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a public health concern worldwide. Ensitrelvir (S-217622) has been evaluated as an antiviral treatment for COVID-19, targeting SARS-CoV-2 3C-like protease (3CL(pro)). Ensi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawashima, Sho, Matsui, Yuki, Adachi, Takumi, Morikawa, Yuji, Inoue, Kae, Takebayashi, Shiori, Nobori, Haruaki, Rokushima, Masatomo, Tachibana, Yuki, Kato, Teruhisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Inc. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839456/ https://www.ncbi.nlm.nih.gov/pubmed/36689809 http://dx.doi.org/10.1016/j.bbrc.2023.01.040

Ejemplares similares

Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo
por: Kuroda, Takayuki, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model
por: Fukao, Keita, et al.
Publicado: (2023)

Targeted amplicon sequencing of wastewater samples for detecting SARS-CoV-2 variants with high sensitivity and resolution
por: Kuroiwa, Miho, et al.
Publicado: (2023)

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19
por: Unoh, Yuto, et al.
Publicado: (2022)

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
por: Ip, Jonathan Daniel, et al.
Publicado: (2023)

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2022)

Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
por: Lin, Mengmeng, et al.
Publicado: (2023)

Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease
por: Noske, Gabriela Dias, et al.
Publicado: (2023)

In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
por: Kiso, Maki, et al.
Publicado: (2023)

Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral Ensitrelvir
por: Kawajiri, Takahiro, et al.
Publicado: (2023)

530. Population Pharmacokinetic Analysis of Ensitrelvir, an Inhibitor of 3C-like (3CL) Protease of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for patients with SARS-Cov-2 Infection
por: Ishibashi, Toru, et al.
Publicado: (2023)

SARS-CoV-2 3CL(pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters
por: Sasaki, Michihito, et al.
Publicado: (2022)

548. Combined Results of the Phase 2a/2b/3 Randomized Controlled Trials of Ensitrelvir for the Treatment of COVID-19 Infection
por: Tsuge, Yuko, et al.
Publicado: (2023)

Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2
por: Yang, Yujian, et al.
Publicado: (2023)

549. Ensitrelvir for the Treatment of COVID-19 Infection: Evaluation of Taste Disorder and Smell Disorder in the Phase 3 Part of the Phase 2/3 SCORPIO-SR Randomized Controlled Trial
por: Tsuge, Yuko, et al.
Publicado: (2023)

Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor
por: Konno, Hiroyuki, et al.
Publicado: (2017)

A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations
por: Shimizu, Ryosuke, et al.
Publicado: (2023)

537. Safety and Effectiveness of Ensitrelvir for the Treatment of COVID-19 in Japanese Clinical Practice: A Post-marketing Surveillance (Interim Analysis)
por: Ogura, Eriko, et al.
Publicado: (2023)

Assessing drug target suitability using TargetMine
por: Chen, Yi-An, et al.
Publicado: (2019)

Effective silicon production from SiCl(4) source using hydrogen radicals generated and transported at atmospheric pressure
por: Okamoto, Yuji, et al.
Publicado: (2020)

A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
por: Mukae, Hiroshi, et al.
Publicado: (2022)

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
por: Iketani, Sho, et al.
Publicado: (2020)

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
por: Iketani, Sho, et al.
Publicado: (2021)

Small change for big improvement in the preparation of the key intermediate N(1), N(3)-disubstituted 1,3,5-triazone of ensitrelvir
por: Hu, Wei, et al.
Publicado: (2023)

Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2023)

Plant Products as Inhibitors of Coronavirus 3CL Protease
por: Mandal, Anirban, et al.
Publicado: (2021)

A simplified cell-based assay to identify coronavirus 3CL protease inhibitors
por: Resnick, Samuel J., et al.
Publicado: (2020)

Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19
por: Hu, Wei, et al.
Publicado: (2022)

Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma
por: Jung, Seowoong, et al.
Publicado: (2023)

Inhibition of SARS-CoV 3CL protease by flavonoids
por: Jo, Seri, et al.
Publicado: (2019)

696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
por: Ito, Akinobu, et al.
Publicado: (2018)

Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
por: Iketani, Sho, et al.
Publicado: (2021)

Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides
por: Kasuya, Takeshi, et al.
Publicado: (2016)

Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: Structure–activity relationship study
por: Thanigaimalai, Pillaiyar, et al.
Publicado: (2013)

Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression
por: Ishibashi, Yuji, et al.
Publicado: (2014)

Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites
por: Iketani, Sho, et al.
Publicado: (2022)

Mechanism of the Maturation Process of SARS-CoV 3CL Protease
por: Hsu, Min-Feng, et al.
Publicado: (2005)

Hypericin Inhibit Alpha-Coronavirus Replication by Targeting 3CL Protease
por: Zhang, Yue, et al.
Publicado: (2021)

Eupatin, a Flavonoid, Inhibits Coronavirus 3CL Protease and Replication
por: Park, Yea-In, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vkkq9cgvm1qng64c5mjtudprgk